Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

The bank's head of blockchain solutions Philippe Meyer told the DigiAssets conference in London that it started advising on ...

Gilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.

The long-short ratio in the perpetual futures market has fallen to 0.9298, indicating bearish sentiment among traders.